Digestive System Tumor clinical trials at UCSF
3 in progress, 1 open to eligible people
Digestive system tumors are cancers found in organs like the stomach and intestines. UCSF is examining the effectiveness of using radiation therapy on these cancers that have metastasized. By exploring these treatments, UCSF gathers important information about managing advanced digestive cancers.
Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
open to eligible people ages 18 years and up
This phase II trial studies how well radiation therapy works for the treatment of gastrointestinal cancer that are spreading to other places in the body (metastatic). Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. This trial is being done to determine if giving radiation therapy to patients who are being treated with immunotherapy and whose cancers are progressing (getting worse) can slow or stop the growth of their cancers. It may also help researchers determine if giving radiation therapy to one tumor can stimulate the immune system to attack other tumors in the body that are not targeted by the radiation therapy.
San Francisco 5391959, California 5332921
ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
Sorry, in progress, not accepting new patients
- To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advanced GI malignancies. - To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with other cancer therapies. - To evaluate the antitumor activity of ERAS-007 in combination with other cancer therapies. - To evaluate the PK profiles of ERAS-007 and other cancer therapies when administered in combination.
San Francisco 5391959, California 5332921 and other locations
TheraSphere With Durvalumab and Tremelimumab for HCC
Sorry, in progress, not accepting new patients
The objective of the ROWAN clinical study is to assess the efficacy of local tumor control in HCC patients who receive TheraSphere followed by durvalumab and tremelimumab.
San Francisco 5391959, California 5332921 and other locations
Our lead scientists for Digestive System Tumor research studies include Mary Feng.
Last updated: